Genvoya clinical trials?

Here’s a concise overview of the key clinical trial data for Genvoya (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide, or EVG/COBI/FTC/TAF):

What Genvoya was studied for
- Treatment-naive HIV-1 infection: efficacy and safety in adults and adolescents starting therapy.
- Switch studies: efficacy and safety when switching virologically suppressed patients from other regimens (including TDF-based regimens) to Genvoya.
- Pediatric/adolescent data: safety and efficacy in teens 12 years and older (weight typically ≥35 kg).
- Long-term use: extension studies looking at durability of response beyond 48 weeks.

Key trial findings
- ART-naive (initial therapy)
- Genvoya was noninferior to Stribild (the older 4-drug EVG/COBI/FTC/TDF regimen) in maintaining virologic suppression (HIV-1 RNA <50 copies/mL) at about 48 weeks.
- Efficacy was similar between the two regimens.
- Safety profile: overall similar virologic efficacy, but Genvoya offered potential renal and bone safety advantages over TDF-containing regimens in the long term, due to the tenofovir alafenamide (TAF) backbone replacing TDF.

- Switch from TDF-containing regimens
- Switching virologically suppressed patients from TDF-containing regimens (e.g., those including Stribild) to Genvoya generally maintained viral suppression.
- Beneficial changes in renal/tubular safety markers and increases (or stabilization) in bone mineral density have been observed after switching, reflecting the more favorable renal/bone safety profile of TAF vs TDF.

- Pediatric/adolescent data
- In adolescents (12–18 years old) weighing at least about 35 kg, Genvoya demonstrated virologic suppression rates and safety similar to adults in the studied populations.

- Durability/longer-term data
- Extension studies have shown that virologic suppression with Genvoya is durable for longer timeframes (up to roughly 96–144 weeks in some trials), with continued favorable renal and bone safety signals compared with older TDF-containing regimens.

Safety profile and considerations
- Common adverse events seen in trials are generally similar to other first-line regimens and include GI symptoms (e.g., nausea, diarrhea) and headache.
- Renal and bone safety: Genvoya (TAF backbone) tends to have more favorable renal and bone safety markers than TDF-containing regimens, especially with long-term use; this is a key driver for choosing Genvoya over TDF-based options in suitable patients.
- Drug interactions: as a cobicistat-boosted regimen, Genvoya can interact with other medications metabolized by CYP3A or renal transporters. Careful review of concomitant meds is advised.

What you might want next
- If you’d like, I can pull the names of the exact pivotal trials and give you citations (including NEJM/Lancet/JAMA papers and the FDA labeling) for ART-naive data, switch studies, and adolescent data.
- I can also summarize the FDA-approved labeling specifics (indications, dosing, renal function requirements, and key warnings) if you’re preparing for a medical consult or patient counseling.

Would you like me to fetch the trial names and full citations, or focus on a particular aspect (e.g., ART-naive efficacy, switch outcomes, or pediatric data)?